China has officially launched the second phase of its pilot program for Laboratory Developed Tests (LDTs), marking another significant step in promoting innovation and self-reliant diagnostic capabilities across its healthcare system.

Original from: Diasorin - REVENUES: € 619 MILLION, +5% COMPARED TO H1¡¯24 (+6% AT CER, +8% AT CER AND EXCLUDING COVID REVENUES), CONFIRMING THE FY¡¯25 GUIDANCE; - ADJUSTED1 EBITDA2: € 214 MILLION..

President Donald Trump has demanded ¡°binding commitments¡± from 17 pharmaceutical companies to lower drug prices, escalating his efforts to cut consumer costs and sending their share prices lower.

Siemens Healthineers AG today announces its results for the third quarter of fiscal year 2025 ended June 30, 2025.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the BD Veritor™ System for SARS-CoV-2, a digital test designed to detect COVID-19 antigens in symptomatic individuals in about 15 minutes at doctors' offices, urgent care centers, retail clinics and other convenient points of care.

Original from: Merck ¡¤ Total Worldwide Sales Were $15.8 Billion, a Decrease of 2% From Second Quarter 2024 Both Nominally and Excluding the Impact of Foreign Exchange - KEYTRUDA Sales Were $8.0 ..

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today PGDx elio™ tissue completeopens in a new tab has been CE-marked under the European Union's (EU) new In Vitro Diagnostic Regulation (IVDR). It is now the first and only test of its kind in the EU CE-marked for comprehensive solid tumor profiling. This marks a significant milestone in expanding access to personalized treatment options for the approximately 2.7 millionopens in a new tab people diagnosed with cancer every year in the EU.

1.4 Blood and Electrolytes/Coagulation The boundaries between the POCT and laboratory-based systems for blood and electrolyte testing are somewhat blurred, and instruments can be used in multiple scenarios. The ..

Revvity, Inc. (NYSE: RVTY), today reported financial results for the second quarter ended June 29, 2025.

Agilent Technologies Inc. (NYSE: A) announced the recent signing of a Memorandum of Understanding (MOU) with the Nanyang Environment & Water Research Institute (NEWRI), outlining their collaboration in advancing environmental and water research over the next three years.

Over 40 IVD Companies Support Chikungunya Virus Diagnosis Amid WHO Alert On July 22, the World Health Organization (WHO) issued a global alert concerning chikungunya, a mosquito-borne disease, urging cou..

Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, received FDA approval to streamline the stool collection process for ColoSense®, its RNA-based colorectal cancer (CRC) screening test. The newly approved collection kit no longer requires patients to separate their sample into multiple containers. This improves ease of use and reduces barriers to at-home screening,¹ while maintaining clinical performance.

Mirxes said Wednesday that is has partnered with Nagawa Pharmaceutical to accelerate development and implementation of its early cancer screening tests across Japan.

Original from: Labcorp Raises Full-Year Guidance ¡¤ Financial results from Operations for second quarter 2025 versus second quarter 2024: - Revenue: $3.53 billion versus $3.22 billion ..

Original from: Roche ¡¤ Elecsys pTau181 is the first In Vitro Diagnostic Regulation (IVDR) certified test to rule out Alzheimer¡¯s associated amyloid pathology. ¡¤ The minimally invasive, blood-bas..

Australian molecular diagnostics developer Genetic Signatures has signed a strategic partnership with lab automation solutions provider Tecan and in vitro diagnostic software developer Repado. Announced on Tuesday, the partnership aims to create a scalable suite of fully integrated syndromic infectious disease testing systems. Financial terms were not disclosed.

Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended June 27, 2025.

1.2 Cardiovascular Diseases (Cardiac Markers) Cardiovascular disease remains the leading cause of death worldwide. More than half a billion people around the world continue to be affected by cardiovascular disea..

Orient Gene's Respiratory Multiplex Tests Get Approved in New Zealand and Brazil Recently, some partner clients of Orient Gene have obtained registration approval from New Zealand¡¯s Medsaf..

Shares of Oxford Nanopore Technologies jumped 16 percent on Monday after the company reported strong preliminary revenues for the first half of 2025.